| Authors: |
Sekeres MA; Division of Hematology, Sylvester Cancer Center, University of Miami, Miami, FL., DeZern AE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD., Otterstatter M; The Emmes Company, Rockville, MD., Padron E; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Al Baghdadi T; Trinity Health, Ann Arbor, MI., Foran JM; Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL., Komrokji RS; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Abel GA; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA., Saber W; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Gore SD; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD., Lee C; Division of Cancer Prevention, National Cancer Institute, Rockville, MD., Bejar R; Division of Hematology and Cellular Therapy, University of California San Diego, San Diego, CA., Liu JJ; Illinois Cancer Care, Peoria, IL.; Heartland NCI Community Oncology Research Program, Decatur, IL., Deeg HJ; Clinical Research Division, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA., Sherman S; The Emmes Company, Rockville, MD., Lindsley RC; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA., Walter MJ; Department of Medicine, Division of Oncology, Washington University, St. Louis, MO., Gillis N; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. |
